Florianopolis, Brazil - The CDCN is sharing research breakthroughs with physicians and researchers around the world and seeking researchers to join their efforts. CDCN co-founders, Drs. David Fajgenbaum and Frits van Rhee, presented their new model of pathogenesis and classification system at HEMO, the Brazilian Congress on Hematology and Hematotherapy, in Florianopolis, Brazil. HEMO is the fourth largest hematology conference in the world. Dr. Fajgenbaum focused on recent advances in understanding the pathogenesis and appropriate subclassification of the disease. Dr. van Rhee shared updates on diagnosis and treatment options for Castleman disease patients. The two speakers were among approximately 100 invited speakers from around the world.
HEMO was the third presentation for Drs. Fajgenbaum and van Rhee at a national or international meeting out of four that will occur this Fall. In September, they proposed a new sub classification system to the Centers for Medicare/Medicaid Services. In October, they presented at the American Society of Clinical Pathology (ASCP) annual meeting along with world-famous hematopathologist, Dr. Ahmet Dogan, from Memorial Sloan-Kettering Cancer Center. In December, the team will lead the CDCN's third annual "Accelerating Research & Treatments for Castleman disease" meeting at the American Society of Hematology (ASH) annual meeting in San Francisco.